Exhibit 99.1
Immunocore Holdings plc
Unaudited Condensed Consolidated Interim Financial Statements

Unaudited Condensed Consolidated Statements of Profit / (Loss) and Comprehensive (Loss) / Income

         
Three Months Ended
September 30,
   
Nine Months Ended
September 30,
 
   
Notes
   
2023
£’000
   
2022
£’000
   
2023
£’000
   
2022
£’000
 
Product revenue, net
   
3
     
49,719
     
33,252
     
137,285
     
64,926
 
Pre-product revenue, net
   
3
     
     
3,051
     
     
9,588
 
Total revenue from sale of therapies
           
49,719
     
36,303
     
137,285
     
74,514
 
Collaboration revenue
   
3
     
1,769
     
4,896
     
6,508
     
21,161
 
Total revenue
           
51,488
     
41,199
     
143,793
     
95,675
 
                                         
Cost of product revenue
           
(220
)
   
(63
)
   
(1,284
)
   
(345
)
Research and development expenses
           
(31,679
)
   
(23,301
)
   
(88,895
)
   
(62,032
)
Selling and administrative expenses
   
4
     
(20,288
)
   
(11,663
)
   
(87,473
)
   
(50,579
)
Operating (loss) / profit
           
(699
)
   
6,172
     
(33,859
)
   
(17,281
)
                                         
Finance income
   
5
     
4,091
     
597
     
10,049
     
725
 
Finance costs
           
(1,632
)
   
(1,785
)
   
(4,817
)
   
(4,515
)
Net finance income / (costs)
           
2,459
     
(1,188
)
   
5,232
     
(3,790
)
                                         
Profit / (loss) before taxation
           
1,760
     
4,984
     
(28,627
)
   
(21,071
)
Income tax credit / (charge)
   
6
     
144
     
1,244
     
(243
)
   
5,050
 
Profit / (loss) for the period
           
1,904
     
6,228
     
(28,870
)
   
(16,021
)
                                         
Other comprehensive loss
                                       
Other comprehensive loss that is or may be reclassified to profit or loss in subsequent periods:
                                       
Exchange differences on translation of foreign operations
           
(2,603
)
   
(1,730
)
   
(1,169
)
   
(1,848
)
Total other comprehensive loss for the period
           
(2,603
)
   
(1,730
)
   
(1,169
)
   
(1,848
)
                                         
Total comprehensive (loss) / income for the period
           
(699
)
   
4,498
     
(30,039
)
   
(17,869
)
Basic  earnings / (loss) per share - £
   
7
     
0.04
     
0.13
     
(0.59
)
   
(0.36
)
Diluted earnings / (loss) per share - £
   
7
     
0.04
     
0.12
     
(0.59
)
   
(0.36
)

The accompanying notes form part of these unaudited condensed consolidated interim financial statements.


Immunocore Holdings plc
Unaudited Condensed Consolidated Interim Financial Statements

Unaudited Condensed Consolidated Statements of Financial Position as at

   
Notes
   
September 30,
2023
£’000
   
December 31,
2022
£’000
 
Non-current assets
                 
Property, plant and equipment
   
8
     
8,025
     
6,472
 
Intangible assets
           
1,589
     
410
 
Right of use assets
            25,832
      25,173
 
Other non-current assets
           
8,846
     
7,342
 
Deferred tax asset
   
6
     
4,135
     
4,240
 
Total non-current assets
           
48,427
     
43,637
 
Current assets
                       
Inventory
           
1,857
     
943
 
Trade and other receivables
   
9
     
49,880
     
46,711
 
Tax receivable
   
6
     
     
11,688
 
Cash and cash equivalents
           
363,955
     
332,539
 
Total current assets
           
415,692
     
391,881
 
Total assets
           
464,119
     
435,518
 
Equity
                       
Share capital
   
10
     
99
     
97
 
Share premium
           
146,205
     
123,751
 
Foreign currency translation reserve
           
(4,266
)
   
(3,097
)
Other reserves
           
337,847
     
337,847
 
Share-based payment reserve
   
11
     
101,781
     
81,411
 
Accumulated deficit
           
(290,123
)
   
(261,253
)
Total equity
           
291,543
     
278,756
 
Non-current liabilities
                       
Non-current accruals
           
2,531
     
1,479
 
Interest-bearing loans and borrowings
           
38,484
     
39,500
 
Deferred revenue
   
3
     
4,331
     
4,331
 
Lease liabilities
           
29,469
     
28,248
 
Provisions
           
153
     
114
 
Total non-current liabilities
           
74,968
     
73,672
 
Current liabilities
                       
Trade and other payables
   
12
     
93,135
     
75,076
 
Corporation tax liability
   
6
     
367
     
 
Interest-bearing loans and borrowings             1,024
      -
 
Deferred revenue
   
3
     
1,602
     
6,408
 
Lease liabilities
           
1,445
     
1,555
 
Provisions
           
35
     
51
 
Total current liabilities
           
97,608
     
83,090
 
Total liabilities
           
172,576
     
156,762
 
Total equity and liabilities
           
464,119
     
435,518
 
 
The accompanying notes form part of these unaudited condensed consolidated interim financial statements.


Immunocore Holdings plc
Unaudited Condensed Consolidated Interim Financial Statements

Unaudited Condensed Consolidated Statements of Changes in Equity

   
Notes
   
Share
capital
£’000
   
Share
premium
£’000
   
Foreign
currency
translation
reserve
£’000
   
Share-
based
payment
reserve
£’000
   
Other
reserve
£’000
   
Accumulated
deficit
£’000
   
Total
equity
£’000
 
At January 1, 2023
         
97
     
123,751
     
(3,097
)
   
81,411
     
337,847
     
(261,253
)
   
278,756
 
Loss for the period
         
     
     
     
     
     
(28,870
)
   
(28,870
)
Other comprehensive loss
         
     
     
(1,169
)
   
     
     
     
(1,169
)
Total comprehensive loss for the period
         
     
     
(1,169
)
   
     
     
(28,870
)
   
(30,039
)
Exercise of share options
 
10, 11
     
2
     
22,454
     
     
     
     
     
22,456
 
Equity-settled share-based payment transactions
 
11
     
     
     
     
20,370
     
     
     
20,370
 
At September 30, 2023
         
99
     
146,205
     
(4,266
)
   
101,781
     
337,847
     
(290,123
)
   
291,543
 
 
   
Notes
   
Share
capital
£’000
   
Share
premium
£’000
   
Foreign
currency
translation
reserve
£’000
   
Share-
based
payment
reserve
£’000
   
Other
reserve
£’000
   
Accumulated
deficit
£’000
   
Total
equity
£’000
 
At January 1, 2022
         
88
     
212,238
     
89
     
54,357
     
386,167
     
(481,392
)
   
171,547
 
Loss for the period
         
     
     
     
     
     
(16,021
)
   
(16,021
)
Other comprehensive loss
         
     
     
(1,848
)
   
     
     
     
(1,848
)
Total comprehensive loss for the period
         
     
     
(1,848
)
   
     
     
(16,021
)
   
(17,869
)
Exercise of share options
         
1
     
4,535
     
     
     
     
     
4,536
 
Capital reduction in Group's parent company
         
     
(213,043
)
   
     
     
(48,320
)
   
261,363
     
 
Issue of share capital
         
7
     
116,417
     
     
     
     
     
116,424
 
Equity-settled share-based payment transactions
   
11
     
     
     
     
20,181
     
     
     
20,181
 
At September 30, 2022
           
96
     
120,147
     
(1,759
)
   
74,538
     
337,847
     
(236,050
)
   
294,819
 

The accompanying notes form part of these unaudited condensed consolidated interim financial statements.


Immunocore Holdings plc
Unaudited Condensed Consolidated Interim Financial Statements

Unaudited Condensed Consolidated Statements of Cash Flows

         
Nine Months Ended
September 30,
 
   
Notes
   
2023
£’000
   
2022
£’000
 
Cash flows from operating activities
                 
Loss for the period
         
(28,870
)
   
(16,021
)
Adjustments for:
                     
Equity settled share-based payment expense
   
11
     
20,370
     
20,181
 
Depreciation
           
3,969
     
4,794
 
Net finance (income) / costs
           
(5,232
)
   
3,790
 
Foreign exchange movements
           
(550
)
   
(20,498
)
Other
           
11
     
(1
)
Income tax charge / (credit)
           
243
     
(5,050
)
Working capital adjustments:
                       
Increase in trade and other receivables and other non-current assets
           
(4,894
)
   
(25,021
)
Increase in trade and other payables
           
18,717
     
27,501
 
Decrease in current and non-current deferred revenue
           
(4,806
)
   
(20,177
)
Other working capital movements
           
175
     
(807
)
Cash used in operations
           
(867
)
   
(31,309
)
R&D tax credits received
   
6
     
12,566
     
 
Taxation paid
   
6
     
(180
)
   
(614
)
Net cash from / (used in) operating activities
           
11,519
     
(31,923
)
Cash flows from investing activities
                       
Proceeds from sale of property, plant and equipment
           
     
5
 
Purchase of property, plant and equipment
           
(3,776
)
   
(869
)
Purchase of intangible assets
           
(1,178
)
   
 
Interest income receipts
           
9,407
     
725
 
Net cash flows from / (used in) investing activities
           
4,453
     
(139
)
Cash flows from financing activities
                       
Gross proceeds from issue of share capital
           
     
116,812
 
Costs from issue of share capital
           
     
(388
)
Exercise of share options
   
10, 11
     
22,456
     
4,536
 
Interest paid
           
(5,077
)
   
(3,050
)
Repayment of lease liabilities
           
(1,117
)
   
(2,265
)
Net cash flows from financing activities
           
16,262
     
115,645
 
Increase in cash and cash equivalents
           
32,234
     
83,583
 
Net foreign exchange difference on cash held
           
(818
)
   
25,720
 
Cash and cash equivalents at beginning of the period
           
332,539
     
237,886
 
Cash and cash equivalents at end of the period
           
363,955
     
347,189
 

The accompanying notes form part of these unaudited condensed consolidated interim financial statements.


Immunocore Holdings plc
Unaudited Condensed Consolidated Interim Financial Statements

Notes to the Financial Statements

1. Organization and nature of business

General information

Immunocore Holdings plc (the “Company”) is a public limited company incorporated in England and Wales and has the following wholly owned subsidiaries: Immunocore Limited, Immunocore LLC, Immunocore Commercial LLC, Immunocore Ireland Limited, Immunocore GmbH, and Immunocore Nominees Limited (collectively referred to as the “Group”).

The Company’s American Depositary Shares (“ADSs”) began trading on the Nasdaq Global Select Market under the ticker symbol “IMCR” on February 5, 2021, following its initial public offering (“IPO”). The IPO and concurrent private placement generated net proceeds of £210,985,000 ($286,887,000) after underwriting discounts, commissions and directly attributable offering expenses. In July 2022, the Company raised net proceeds of £116,424,000 ($139,515,000) through the sale of its ordinary shares in the form of ADSs and non-voting ordinary shares in a private placement.

The principal activity of the Group is pioneering the development and sale of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, the Group is developing a deep pipeline in multiple therapeutic areas, including four clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs.

In 2022, the Group received approval for its lead product, KIMMTRAK, for the treatment of unresectable metastatic uveal melanoma from the U.S. Food and Drug Administration the European Commission and other health authorities. KIMMTRAK is now approved in over 35 countries and the Group has commercially launched in the United States, Germany and France, among other territories, with further commercial launches underway in additional territories where it has received approval.

2. Significant accounting policies

Basis of preparation and statement of compliance

The unaudited condensed consolidated interim financial statements (“interim financial statements”) as at and for the three and nine months ended September 30, 2023 and 2022 have been prepared in accordance with International Accounting Standard 34, “Interim Financial Reporting” (“IAS 34”). The accounting policies, including the Group’s Critical accounting estimates, applied in these interim financial statements are the same as those applied in the Group’s consolidated financial statements as at and for the year ended December 31, 2022.

The unaudited condensed consolidated interim financial statements do not include all of the information required for the full annual financial statements and should be read in conjunction with the annual consolidated financial statements of the Group for the year ended December 31, 2022 included in the Company’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission on March 1, 2023 (the “Annual Report”).

The unaudited condensed consolidated interim financial statements have been prepared under the historical cost basis, as modified by the recognition of certain financial instruments measured at fair value and are presented in pounds sterling which is the Company’s functional currency. All values are rounded to the nearest thousand, except where otherwise indicated.

Date of authorization

These unaudited condensed consolidated interim financial statements were approved by the Board of Directors (the “Board”) on November 7, 2023, and signed on its behalf by Dr. Bahija Jallal, Chief Executive Officer.

Adoption of new accounting standards

There have been no new accounting standards adopted by the Group in the three and nine months ended September 30, 2023 which have had a material impact on these unaudited condensed consolidated interim financial statements. There are no standards issued but not yet effective that the Group expects to have a material impact on its financial statements.


Going concern

The Group reported cash and cash equivalents of £363,955,000 and net current assets of £318,084,000 at September 30, 2023, with an operating loss for the three and nine months ended September 30, 2023 of £699,000 and £33,859,000 respectively, and net cash from operating activities for the nine months ended September 30, 2023 of £11,519,000. The positive operational cash inflow was largely due to R&D tax credits received, and generated net product revenue of £49,719,000 and £137,285,000 for the three and nine months ended September 30, 2023, respectively.

In assessing the going concern assumptions, management has undertaken an assessment of the current business and strategy forecasts covering a twelve month period, which includes anticipated KIMMTRAK revenue. In assessing the downside risks, the Board has also considered scenarios incorporating a range of revenue arising from KIMMTRAK sales. As part of considering the downside risks, the Board has considered the impact of the current macroeconomic environment, such as the effects of pandemics or epidemics and other potential economic impacts including the war in Ukraine and the conflict between Hamas and Israel, and related geopolitical tensions, as well as global inflation, liquidity concerns at banks and financial institutions, capital market instability, interest and exchange rate fluctuations, and increases in commodity, energy and fuel prices as well as supply chain disruptions. The Board has concluded that while these may have a future impact on the Group’s business and implementation of its strategy and plans, it anticipates that any such impact will be minimal on clinical trials or other business activities over the period assessed for going concern purposes. As of the date of these financial statements, the Group is not aware of any specific event or circumstance that would require the Group to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from these estimates, and any such differences may be material to the Group’s financial statements.

Given the current cash position and the assessment performed, the Board believes that the Group will have sufficient funds to continue to meet its liabilities as they fall due for a period of at least twelve months from the date of issue of these unaudited condensed consolidated interim financial statements and therefore, the Group has prepared the financial statements on a going concern basis. This scenario is based on the Group’s lower range of anticipated revenue levels. As the Group continues to incur significant expenses in the pursuit of its business strategy, including further commercialization and marketing plans for KIMMTRAK, additional funding will be needed before further existing clinical and preclinical programs may be expected to reach commercialization, which would potentially lead to additional operational cash inflows. Until the Group can generate revenue from product sales sufficient to fund its ongoing operations and further develop its pipeline, if ever, it expects to finance its operations through a combination of public or private equity offerings and debt financings or other sources, such as potential collaboration agreements, strategic alliances and licensing arrangements.

Estimates and judgments

The preparation of the unaudited condensed consolidated interim financial statements in conformity with IAS 34 requires management to make judgments, estimates and assumptions. These judgments, estimates and assumptions affect the reported assets and liabilities as well as contingent liabilities and income and expenses in the financial period. The estimates and associated assumptions are based on information available when the unaudited condensed consolidated interim financial statements are prepared, historical experience and various other factors which are believed to be reasonable under the circumstances the results of which form the basis of making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the Group’s control. Hence, estimates may vary from the actual values. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or the period of revision and future periods if this revision affects both current and future periods.

Judgments and estimates made, including Critical accounting estimates, together with the Group’s significant accounting policies, are disclosed in the consolidated financial statements of the Group for the year ended December 31, 2022, and are presented in the Group’s Annual Report. There have been no significant updates to the Group’s estimates and accounting policies for the three and nine months ended September 30, 2023.

Segmental reporting

The Group operates in one operating segment. The Group’s chief operating decision maker, its Chief Executive Officer, manages the Group’s operations on an integrated basis for the purposes of allocating resources.


3. Revenue

Revenue is presented by type, and net of deductions in the table below.

   
For the Three Months Ended
September 30,
   
For the Nine Months Ended
September 30,
 
   
2023
£’000
   
2022
£’000
   
2023
£’000
   
2022
£’000
 
                         
Product revenue, net
   
49,719
     
33,252
     
137,285
     
64,926
 
Pre-product revenue, net
   
     
3,051
     
     
9,588
 
Total revenue from sale of therapies
   
49,719
     
36,303
     
137,285
     
74,514
 
Collaboration revenue
                               
Eli Lilly
   
     
     
     
7,361
 
Genentech
   
1,769
     
4,896
     
6,508
     
13,800
 
Total collaboration revenue
   
1,769
     
4,896
     
6,508
     
21,161
 
Total revenue
   
51,488
     
41,199
     
143,793
     
95,675
 

Eli Lilly and Genentech are based in the United States. Net product revenue from the sale of KIMMTRAK, and net pre-product revenue from the sale of tebentafusp as part of a compassionate use and early access program are presented by region based on the location of the customer below.

   
For the Three Months Ended
September 30,
   
For the Nine Months Ended
September 30,
 
   
2023
£’000
   
2022
£’000
   
2023
£’000
   
2022
£’000
 
United States
   
34,500
     
22,508
     
96,845
     
48,327
 
Europe
   
15,012
     
13,034
     
39,529
     
25,423
 
Rest of World
   
207
     
761
     
911
     
764
 
Total revenue from sale of therapies
   
49,719
     
36,303
     
137,285
     
74,514
 

Product revenue, net

During the three and nine months ended September 30, 2023, the Group recognized £49,719,000 and £137,285,000 of net product revenue, respectively, relating to the sale of KIMMTRAK primarily in the United States and Europe following marketing approvals in 2022 and subsequent commercial launches. Revenue is presented after estimated deductions for rebates, chargebacks, other customer fees and returns.

Pre-product revenue, net

There was no pre-product revenue during the three and nine months ended September 30, 2023, following the transition to the commercial sale of KIMMTRAK in France in the second half of 2022. In the three and nine months ended September 30, 2022, the Group recognized £3,051,000 and £9,588,000 of net pre-product revenue, respectively, relating to the sale of tebentafusp under a compassionate use and early access program in France after estimated deductions for rebates and returns.

Genentech Collaboration

During the three and nine months ended September 30, 2023, the Group recognized £1,769,000 and £6,508,000 of revenue, respectively, relating to the 2018 Genentech agreement and IMC-C103C (for the three and nine months ended September 30, 2022: £4,896,000 and £13,800,000).

In February 2023, Genentech accepted our proposal to cease co-funding the development of MAGE-A4 HLA-A02 targeted programs, except for our equal share of the wind-down costs of the IMC-C103C Phase 1 clinical trial.

Eli Lilly Collaboration

During the three and nine months ended September 30, 2023, the Group recognized no revenue relating to the Eli Lilly Collaboration (for the three and nine months ended September 30, 2022: £nil and £7,361,000, respectively).

The Group released the remaining deferred revenue attributed to the third target under the Eli Lilly Collaboration after the parties agreed to terminate the agreement with Eli Lilly during the three months ended March 31, 2022.


Deferred revenue

Of the total revenue recognized during the three and nine months ended September 30, 2023, £1,602,000 and £4,806,000, respectively, was included in deferred revenue at January 1, 2023. No collaboration revenue was recognized in the three and nine months ended September 30, 2023 relating to performance obligations satisfied in previous years (for the three and nine months ended September 30, 2022: £nil). The remaining current deferred revenue as at September 30, 2023 relates to the Genentech agreement. The Group expects to recognize this remaining revenue within the next year.

Non-current deferred revenue in the unaudited condensed consolidated interim statement of financial position as at September 30, 2023 and December 31, 2022, respectively, relates to the Group’s non-refundable payment of £4,331,000 received from Medison Pharma Ltd (“Medison”) in the year ended December 31, 2022. The Group expects to recognize revenue for this combined performance obligation of supplying KIMMTRAK and granting Medison the exclusive right to distribute KIMMTRAK in South America with the sale of products following regulatory approval in South America. The Group estimates that Product revenue recognition of this Non-current deferred revenue will commence later than September 30, 2024.

4. Selling and administrative expenses

There were £9,298,000 of foreign exchange gains and £108,000 of foreign exchange losses, which the Group classifies within Selling and administrative expenses, for the three and nine months ended September 30, 2023, respectively, compared to gains of £15,184,000 and £24,343,000 in the three and nine months ended September 30, 2022, respectively. These gains and losses arise on a number of foreign currency items, including the translation of monetary foreign currency balances in the Group’s main operating subsidiary in the United Kingdom.

5. Finance income

Finance income increased in the three and nine months ended September 30, 2023 due to higher interest rates and higher levels of cash and cash equivalents held by the Group in the three and nine months ended September 30, 2023 compared to the three and nine months ended September 30, 2022.

6. Income tax

Income tax credit/ (charge) is recognized at an amount determined by multiplying the profit / (loss) before taxation for the interim reporting period by the Group’s best estimate of the weighted-average annual income tax rate expected for the full financial year, adjusted for the tax effect of certain items recognized in full in the interim period. As such, the effective tax rate in the interim financial statements may differ from the Group’s estimate of the effective tax rate for the annual financial statements.

The Group’s consolidated estimated effective tax credit rate for the three months ended September 30, 2023 and effective tax rate for the nine months ended September 30, 2023 was 8.2% and 0.8% (tax credit rate for the three and nine months ended September 30, 2022: 25.0% and 24.0%). During the three and nine months ended September 30, 2023, the Company recorded a tax credit of £144,000 and a tax charge of £243,000, respectively, compared to tax credits for the three and nine months ended September 30, 2022 of £1,244,000 and £5,050,000. Historically, the Group satisfied the definition of a Small and Medium-sized Enterprise (“SME”), and was able to surrender some of its U.K. tax losses for a cash rebate of up to 33.35% of expenditures related to eligible research and development projects. The Group exceeded the size limit thresholds and no longer qualifies for tax relief under the U.K. SME research and development regime in 2023. The Group will continue to benefit from the U.K. large company, Research & Development Expenditure Credit (“RDEC”) regime which can generate a cash rebate of up to 10.53% of qualifying research and development expenditures incurred prior to 1 April 2023 and 15% for expenditure incurred after this date. The Group records tax credits receivable under the SME research and development tax credit regime within income tax credit / (charge). Tax credits receivable under the large company RDEC regime are recorded ‘above the line’ as a reduction from research and development expenses.

A deferred tax asset of £4,135,000 has been recognized as of September 30, 2023 (December 31, 2022: £4,240,000) primarily representing unused tax credits carried forward for one of the Group’s U.S. subsidiaries, Immunocore LLC, following an annual assessment, or periodically as required, of all available and applicable information, including its forecasts of costs and future profitability and the resulting ability to reverse the recognized deferred tax assets over a short period of time.

During the nine months ended September 30, 2023, the Group received U.K. tax credits of £12,566,000 relating to research and development expenditure in the year ended December 31, 2021 and 2022 (for the nine months ended September 30, 2022, no tax credits were received). During the nine months ended September 30, 2023, the Group made tax payments of £180,000 in relation to estimated U.S. corporate income taxes for 2023.


7. Basic and diluted earnings / (loss) per share
 
   
For the Three Months Ended
September 30,
   
For the Nine Months Ended
September 30,
 
   
2023
   
2022
   
2023
   
2022
 
Profit / (loss) for the period (£’000s)
   
1,904
     
6,228
     
(28,870
)
   
(16,021
)
Basic weighted average number of shares
   
49,134,037
     
46,998,420
     
48,671,732
     
44,944,827
 
Adjustment for stock options with dilutive effect
   
5,024,930
     
4,444,856
     
     
 
Diluted weighted average number of shares
   
54,158,967
     
51,443,276
     
48,671,732
     
44,944,827
 
Basic earnings / (loss) per share (£)
   
0.04
     
0.13
     
(0.59
)
   
(0.36
)
Diluted earnings / (loss) per share (£)
   
0.04
     
0.12
     
(0.59
)
   
(0.36
)

Basic and diluted earnings / (loss) per share is calculated by dividing the profit or loss for the period attributable to the equity holders of the Group by the weighted average number of ordinary shares outstanding during the period, including ordinary shares represented by ADSs. For the nine months ended September 30, 2023 and 2022, the dilutive effect of potential shares through equity settled transactions is considered to be anti-dilutive as they would decrease the loss per share and are, therefore, excluded from the calculation of diluted loss per share. For the three months ended September 30, 2023 and 2022, there were 902,650 and 88,695, respectively, ordinary shares issuable upon the exercise of options granted under the Group’s option plans excluded from the calculation for diluted earnings per share, because they are considered to be anti-dilutive.

8. Property, plant and equipment

During the three and nine months ended September 30, 2023, the Group acquired assets at a cost of £787,000 and £4,025,000, respectively, relating primarily to laboratory equipment.

9. Trade and other receivables

   
September 30,
2023
£’000
   
December 31,
2022
£’000
 
Trade receivables
   
33,438
     
27,736
 
Other receivables
   
4,739
     
7,682
 
Prepayments and accrued income
   
11,703
     
11,293
 
     
49,880
     
46,711
 

Included within prepayments and accrued income are amounts paid in advance for clinical trials that are expected to be received in services or repaid within twelve months.

10. Share capital

Issued share capital
 
Ordinary
   
Deferred
 
(0.2p per share, except deferred shares which are 0.01p per share)
 
shares
   
shares
 
At January 1, 2023
   
48,088,346
     
5,793,501
 
Exercise of share options
   
1,349,910
     
 
At September 30, 2023
   
49,438,256
     
5,793,501
 

11. Share-based payments

During the three and nine months ended September 30, 2023 the total charge for share-based payments was £6,719,000 and £20,370,000 respectively (for the three and nine months ended September 30, 2022, £6,093,000 and £20,181,000, respectively).

The Group granted 27,360 and 2,100 options to purchase ordinary shares under the Group’s 2021 Equity Incentive Plan in the three months ended September 30, 2023 and 2022 respectively, and 769,465 and 1,365,753 options in the nine months ended September 30, 2023 and 2022, respectively. The options in both periods were valued using the Black-Scholes model, with the majority vesting over a four-year period from the date of grant, and with 25% of the award vesting at the end of the first year and the remaining award vesting quarterly over the following three years. The weighted average fair value and exercise prices of options granted is set out below.

   
For the Three Months Ended
September 30,
   
For the Nine Months Ended
September 30,
 
   
2023
   
2022
   
2023
   
2022
 
   
$
   
$
   
$
   
$
 
Weighted average exercise price
   
59.45
     
37.25
     
63.78
     
25.49
 
Weighted average fair value
   
36.48
     
23.58
     
39.42
     
15.63
 

During the three and nine months ended September 30, 2023, 496,907 and 1,349,910 options with a weighted average exercise price of $21.08 and $20.78, were exercised, respectively. As at September 30, 2023, and 2022, there were 9,251,830 and 9,942,203 outstanding options of which 5,500,611 and 4,661,406 respectively, were exercisable.


12. Trade and other payables

   
September 30,
2023
£’000
   
December 31,
2022
£’000
 
Trade payables
   
11,195
     
11,716
 
Other taxation and social security
   
1,187
     
927
 
Pension liability
   
430
     
34
 
Accruals
   
80,323
     
62,399
 
     
93,135
     
75,076
 

Accruals as at September 30, 2023 include estimates for rebates, chargebacks, other customer fees and returns of £46,515,000 in respect of Product revenue from the sale of KIMMTRAK and Pre-product revenue from the sale of tebentafusp, compared to £24,066,000 as at December 31, 2022. Combined with the Non-current accruals in the unaudited condensed consolidated interim statement of financial position, the Group’s total accruals for such deductions from revenue were £49,046,000 as at September 30, 2023, and £25,545,000 as at December 31, 2022. The increase in these accruals reflects revenue growth in major markets and ongoing sales in Europe prior to the completion of pricing negotiations and settlement of rebates payable.

13. Events after the reporting period

In October 2023, the Group entered into a lease agreement for approximately 19,000 square feet of additional office space in Maryland, United States. Under this agreement, the Group is required to make lease payments until 2035. The lease contains early termination and extension options.